KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Dec 2024 value amounting to $146.2 million.

  • Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) fell 4.59% to $139.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.0 million, marking a year-over-year decrease of 4.59%. This contributed to the annual value of $146.2 million for FY2024, which is 2.07% up from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) is $146.2 million, which was up 2.07% from $143.2 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $146.2 million during FY2024, and registered a low of $118.5 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $143.8 million, with a median of $143.2 million in 2023.
  • Data for Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY grew of 9.70% (in 2022) over the last 5 years.
  • Over the past 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $118.5 million in 2020, then grew by 9.20% to $129.4 million in 2021, then grew by 9.70% to $141.9 million in 2022, then rose by 0.93% to $143.2 million in 2023, then climbed by 2.07% to $146.2 million in 2024.